Virus vaccine could be bad for red hot glove stocks


Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. "Stocks have already rallied a lot, ” Wong said.

KUALA LUMPUR: The recent progress in developing a vaccine for the coronavirus is posing a threat to the meteoric rise of Malaysian glove-maker stocks, one of the hottest sectors in Asia amid the pandemic.

Shares in the sector’s biggest companies such as Top Glove Corp., Hartalega Holdings Bhd. and Supermax Corp. each dropped more than 6% on Tuesday on signs that the Trump administration may fast-track vaccines and treatments for coronavirus.

The U.S. is expanding access to a treatment involving blood plasma from recovered patients and the Financial Times separately reported Trump’s government is considering whether to bypass regulatory standards to accelerate an experimental vaccine.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

House plan sets tax harbour for some stablecoins
Oil advances as US tightens Venezuela blockade
Call to rebuild fiscal buffers
Fitch pushes Gabon’s rating deeper into junk
Store expansion, earnings growth to underpin MyNews positive outlook
Fifth straight week of buying by local institutions
George Kent wins RM34.5mil LRT contract
Swiss court to hear landmark climate case against cement giant
Uber, Baidu to start joint UK robotaxi trials
Paramount eyes 10% ROE on asset optimisation

Others Also Read